JPMorgan upgrades CAMP to Overweight with $9 PT
- JPMorgan analyst Anupam Rama upgraded CAMP4 Therapeutics from Neutral to Overweight on June 16, 2026.
- Price target raised significantly from $5 to $9, implying substantial upside from ~$3.96 close.
- Upgrade highlights strong potential of lead candidate CMP-002 for SYNGAP1-related disorders.
- Company recently presented preclinical data and hosted by JPM in biotech conference series.
- CAMP advancing toward global Phase 1/2 SYNGAP1 trial in 2H 2026 with cash runway into 2028.
- Analyst optimism on RNA-targeting platform drove heavy buying and intraday rally.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.